Literature DB >> 26743192

Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease.

Emmanuel J Favaloro1, Soma Mohammed2.   

Abstract

von Willebrand disease (VWD) is reportedly the most common bleeding disorder and arises from deficiency and/or defects of von Willebrand factor (VWF). Laboratory diagnosis and typing of VWD has important management implications and requires a wide range of tests, including VWF antigen (VWF:Ag) and various activities, involving differential identification of qualitative vs quantitative VWF defects. We have assessed a new hemostasis instrument, the chemiluminescent assay based ACL AcuStar™, and an associated HemosIL AcuStar three test panel comprising VWF:Ag, VWF ristocetin cofactor (VWF:RCo) and VWF collagen binding (VWF:CB) (Instrumentation Laboratory, Bedford, Ma. USA) for ability to identify VWD, to help provisionally type VWD, and for potential use in therapy monitoring. This test system was compared to previously evaluated and validated test systems including VWF:RCo on CS-5100 and BCS analyzers, the new Siemens INNOVANCE assay (VWF Ac) on CS-5100, and VWF:Ag and VWF:CB assays performed by automated ELISA. We employed a large total sample test set (n=535) comprising plasma and platelet-lysate samples from individuals with and without VWD, some on treatment, normal plasmas, and normal and pathological controls. We also evaluated desmopressin (DDAVP) responsiveness, plus differential sensitivity to reduction in high molecular weight (HMW) VWF. The chemiluminescent test panel (VWF:Ag, VWF:RCo, VWF:CB) showed good comparability to similar assays performed by alternate methods, and broadly similar data for identification of VWD, provisional VWD type identification, DDAVP and VWD therapy, and HMW VWF sensitivity, although some notable differences were evident. The chemiluminescent system showed best low level VWF sensitivity, and lowest inter-assay variability, compared to all other systems. In conclusion, we have validated theACL AcuStar and the chemiluminescent HemosIL AcuStar VWF test panel for use in VWD diagnostics, and have identified some favorable characteristics that may improve the future diagnosis of VWD. Crown
Copyright © 2015. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AcuStar; Chemiluminescence; Collagen binding; Diagnosis; Laboratory testing; Ristocetin cofactor; VWD; VWF; von Willebrand disease; von Willebrand factor

Mesh:

Substances:

Year:  2015        PMID: 26743192     DOI: 10.1016/j.thromres.2015.12.010

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

Review 1.  Current challenges in the diagnosis and management of patients with inherited von Willebrand's disease in Italy: an Expert Meeting Report on the diagnosis and surgical and secondary long-term prophylaxis.

Authors:  Piercarla Schinco; Giancarlo Castaman; Antonio Coppola; Dorina Cultrera; Cosimo Ettorre; Anna C Giuffrida; Emanuela Marchesini; Renato Marino; Marta Milan; Claudio Molinari; Simona M Siboni; Ezio Zanon; Augusto B Federici
Journal:  Blood Transfus       Date:  2017-05-26       Impact factor: 3.443

2.  Establishment of an International Reference Reagent for standardization of von Willebrand factor binding to recombinant glycoprotein Ib (VWF:GPIbM and VWF:GPIbR): Official Communication of the SSC.

Authors:  Anthony R Hubbard; Sandra L Haberichter
Journal:  J Thromb Haemost       Date:  2019-05-17       Impact factor: 5.824

3.  Preclinical evaluation of a semi-automated and rapid commercial electrophoresis assay for von Willebrand factor multimers.

Authors:  Marika Pikta; Galina Zemtsovskaja; Hector Bautista; Georges Nouadje; Timea Szanto; Margus Viigimaa; Valdas Banys
Journal:  J Clin Lab Anal       Date:  2018-02-17       Impact factor: 2.352

Review 4.  Rare forms of von Willebrand disease.

Authors:  Emmanuel J Favaloro
Journal:  Ann Transl Med       Date:  2018-09

5.  Bleeding Symptoms and von Willebrand Factor Levels: 30-Year Experience in a Tertiary Care Center.

Authors:  Chatphatai Moonla; Benjaporn Akkawat; Yaowaree Kittikalayawong; Autcharaporn Sukperm; Mukmanee Meesanun; Noppacharn Uaprasert; Darintr Sosothikul; Ponlapat Rojnuckarin
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

Review 6.  Advances in laboratory assessment of thrombosis and hemostasis.

Authors:  Jaewoo Song
Journal:  Blood Res       Date:  2022-04-30

7.  Comparing the quality of testing for von Willebrand disease in different geographic localities.

Authors:  Emmanuel J Favaloro
Journal:  Haemophilia       Date:  2022-01-31       Impact factor: 4.263

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.